Bosutinib for previously treated chronic myeloid leukaemia - NICE TAG TA401

1.1 Bosutinib is recommended as an option, within its marketing authorisation, for chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults, when:

• they have previously had 1 or more tyrosine kinase inhibitor and

• imatinib, nilotinib and dasatinib are not appropriate and

• the company provides bosutinib with the discount agreed in the patient access scheme (as revised in 2016).

https://www.nice.org.uk/guidance/ta401